Cut in Half
Less than a month ago, GreenParts International Inc. (OTCQB: GNPT) stock value soared by 200% on Jan. 27, closing at 30 cents, up 20 cents from the previous day’s close of 10 cents, on a strong volume of 27,200 share.
Fast forward to Feb. 20, 2014: GNPT’s share value has fallen by 50%, closing at 15 cents, down 3 cents from the previous day’s close of 18 cents, on a below-average volume of 6,700 shares.
GreenParts International’s sudden surge in January was most likely a direct result of its Jan. 27 “update,” in which the company strongly hinted that it has some very good fiscal news.
“Our auditors are engaged in preparing for the filing of our Fiscal Year 2013. We are excited about the results and are looking forward to announcing them, once filed,” GNPT chairman and CEO Asif Balagamwala said in a written statement. “We are anticipating another year of growth from our current infrastructure, however, we are very excited about our aggressive plan to be a dynamic growth company in the recycling and waste management industry, by pursuing acquisition targets and developing technologies that save cost and add value to our product line.”
Since then, there hasn’t been a peep from GreenParts International or any news about them anywhere, except the fact the company’s stock has loss one-half of its value in less than a month.
Find out what could be the best investor’s move when it comes to GNPT by getting the complete report here, or by cutting and pasting the following link in your Web browser:
Disappointing Quarterly Results
It’s only been a little more than two weeks since Avanir Pharmaceuticals (NASDAQ:AVNR) reported its disappointing quarterly results for the period ending Dec. 31, 2013.
The San Diego-based pharmaceutical and medical device company reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.43 by $0.50.
It had revenue of $26.70 million for the quarter, compared to the consensus estimate of $24.84 million. During the same quarter in the previous year, the company posted ($0.09) earnings per share. Avanir’s revenue for the quarter was up 61.8% on a year-over-year basis. Analysts forecast that Avanir will post $-0.29 EPS for the current fiscal year.
On Feb. 20, AVNR’s share price closed at $4.05, down 1 cent from the share price of $4.06 the previous day.
Find out what could be the best investor’s move when it comes to AVNR by getting the complete report here, or by cutting and pasting the following link in your Web browser:
Pending Investigations by Law Firms
Since the middle of January, Cleveland BioLabs Inc. (NASDAQ:CBLI), a drug discovery and development company based in Buffalo, N.Y., has found itself being investigated by no less than four law firms on the behalf of some of its shareholders.
One of the law firms announced that its was investigating whether certain alleged statements Cleveland BioLabs made regarding the company’s Jan. 14 public offering were “possible violations of federal securities laws.”
So far, none of the law firms have actually brought a lawsuit against the company. Their investigations are based on allegations that may or may not have merit. So far, Cleveland BioLabs has not responded publicly to the news of the investigations.
In addition to this, Cleveland BioLabs’ Jan. 24th announcement that the Biomedical Advanced Research and Development Authority ("BARDA") had terminated negotiations related to the Company's proposal for further development of Entolimod as a medical radiation countermeasure was not good news.
Of the two analysts that cover Cleveland BioLabs, rates it a “strong buy,” while the other rates it a “hold.”
On Feb. 20, CBLI share price closed at 69 cents, down 3 cents from the share price of 72 cents the previous day.
Find out what could be the best investor’s move when it comes to CBLI by getting the complete report here, or by cutting and pasting the following link in your Web browser:
Long way to go
On Feb 30, pharmaceutical Delcath Systems Inc. (NASDAQ: DCTH) share price closed at 31 cents, down 2 cents from the share price of 33 cents the day before.
There hasn’t been much news about the Stamford, Conn.-based pharmaceutical and medical device company lately.
On Dec. 13, 2013, the company reported that NASDAQ granted it an additional 180 calendar day period, or until June 9, 2014, to regain compliance with the minimum bid price rule. To do so, the bid price of the company's common stock must close at or above $1.00 per share for a minimum of ten consecutive trading days prior to that date.
As of Feb 20, Delcath is less than one-third of the way there.
Find out what could be the best investor’s move when it comes to DCTH by getting the complete report here, or by cutting and pasting the following link in your Web browser:
Sixfigurestockpicks.com issues momentum alerts on stocks that can provide gains to day traders.
Sixfigurestockpicks.com provides members with timely information and exclusive alerts on cheap and under-valued stocks in the United States with the potential to deliver gains of 100% - 200% or more.
Sixfigurestockpicks.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals DailyStockMotion.com is often in the know of several large investor awareness campaigns being deployed.
Timing is everything when trading Penny Stocks. Gain an Edge by joining the Sixfigurestockpicks.com newsletter and receiving alerts from a Pro-Active team of researchers. Trading Alerts believes traders should have a chance at successfully trading penny stocks and invites traders and investors to be part of the Free VIP membership.
Simply sign up for free and start receiving exclusive alerts.
Subscribe Here: http://www.sixfigurestockpicks.com/
Sixfigurestockpicks.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always own due diligence with any potential investment.
Leave a comment...